[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

RAPT Therapeutics President and CEO Brian Russell Wong received a significant stock option grant on June 20, 2025. The derivative securities transaction involved:

• Grant of 637,500 stock options to purchase common stock
• Exercise price set at $7.43 per share
• Options expire on June 19, 2035
• Vesting schedule: 1/48th of shares vest monthly starting June 20, 2025

This Form 4 filing discloses the equity-based compensation grant to Wong, who serves as both Director and CEO. The substantial option grant, which represents direct ownership, appears to be part of the company's executive compensation strategy to align management interests with shareholders over a long-term ten-year period.

Positive

• CEO Brian Russell Wong granted 637,500 stock options with 4-year monthly vesting schedule, aligning long-term interests with shareholders

Negative

• None.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wong Brian Russell

(Last) (First) (Middle)

C/O RAPT THERAPEUTICS, INC.

561 ECCLES AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$7.43	06/20/2025		A		637,500		(1)	06/19/2035	Common Stock	637,500	$0	637,500	D

Explanation of Responses:

1. 1/48th of the shares subject to the option shall vest on each monthly anniversary of the vesting commencement date of June 20, 2025.

	/s/ Rodney Young, Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did RAPT Therapeutics CEO Brian Wong receive on June 20, 2025?

RAPT Therapeutics CEO Brian Wong received 637,500 employee stock options on June 20, 2025, with an exercise price of $7.43 per share.

What is the vesting schedule for RAPT CEO's June 2025 stock option grant?

The stock options vest monthly over 4 years, with 1/48th of the shares vesting each month starting from the vesting commencement date of June 20, 2025.

When do Brian Wong's RAPT stock options expire?

The stock options granted to Brian Wong expire on June 19, 2035, ten years from the grant date.

What positions does Brian Wong hold at RAPT Therapeutics?

Brian Wong serves as both the President and CEO of RAPT Therapeutics, as well as a Director on the company's board.

What was the exercise price of RAPT CEO's June 2025 stock option grant?

The exercise price (conversion price) of the stock options granted to CEO Brian Wong was $7.43 per share.